Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 22 (TRAV22) is a variable (V) gene segment of the alpha chain locus of the T cell receptor (TCR) in humans[2][3][9]. It encodes the V region of the variable domain of the TCR alpha chain that participates in antigen recognition[1][3]. During T cell development, TRAV22 can be rearranged with joining (J) gene segments to form the complete variable region of an alpha chain[2][9]. The assembled TCR, consisting of one alpha and one beta chain, is essential for the recognition of peptide antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells, thus mediating adaptive immune responses[2][4][5][8]. TRAV22 itself is not a therapeutic target, but it contributes to the TCR repertoire diversity[2][10]. Changes or profiling of its usage may be explored in immunological research, but there are no drugs directly targeting TRAV22, and its expression or sequence is not a validated clinical biomarker or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 22 (TRAV22).